Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-12
2006-12-12
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07148248
ABSTRACT:
A leukotriene C4 and D4 antagonist is used to treat or inhibit brain inflammation and sepsis by acting to inhibit increased capillary permeability and white blood cell extravasation. Potential candidate compounds can be screened in a non-human mammal before or after administration of an inflammation inducing agent into the subarachnoid space by determining their ability to inhibit increased capillary permeability and white blood cell extravasation.
REFERENCES:
patent: 5079261 (1992-01-01), Serhan et al.
patent: 5441951 (1995-08-01), Serhan
patent: 2002/0123520 (2002-09-01), Marfat et al.
patent: 0351856 (1990-01-01), None
patent: 0528337 (1993-02-01), None
patent: 0905133 (1999-03-01), None
patent: 1424101 (2004-06-01), None
patent: WO 99/21007 (1999-04-01), None
patent: WO 02/06075 (2002-08-01), None
“Hemorrhagic Syndromes” and “Trauma of the Head”. The Merck Manual of Diagnosis and Therapy (Seventeenth Edition). Merck & Co. Inc., 1999. p. 1424-1431.
XP-001184701-Abstract, Hirabayashi et al., Cysteinyl leukotrienes activate microglia through the CYSLT1 receptor,Society for Neuroscience, 27(1)1160 (Nov.10, 2001).
Zeng et al., Yao Xue Xue Bao, Protective Effect of ONO-1078, A Leukotriene Antagonis on Foca Cerebral Ischemia in Mice,Acta. Pharamaceutics Sinica. 36(2):146-150 (2001) ABSTRACT
Zhang, W., et al., Neuroprotective Effect of ONO-1078, A Leukotriene Receptor Antagonist, on Focal Cerebral Ischemia in Rats,Acta Pharmacol Sin, 23(10):871-877 (2002).
Alvarez Losada, Role of platelet-activating factor, eicosanoids and bradykinin in adjuvant therapy for sepsis, Acta Perdiatrica Espanola, 60(9):535-544 (2002).
Beers and Berkow, Merck manual of diagnosis and theapy,Merck Research Laboratories, 1435-1437 (1999).
Kobayashi et al., Effect of leukotriene antagonist on experimental delayed cerebral vasospasm,Neurosurgery, 31(3):550-556 (1992).
Matsuo et al., Leukotriene B4and C4in cerebrospinal fluid from children with meningitis and febrile seizures,Pediatric Neurology, 14(2):121-124 (1996).
Neuwelt et al., Use of enhanced computerized tomography to evaluate osmotic blood-brain barrier disruption,Neurosurgery, 6(1):49-56 (1980).
Ogata et al., Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice.Infection and Immunity, 60(6):2432-2437 (1992).
Yoshikawa et al., Effect of platelet-activating factor antagonist and leukotriene antagonist on endotoxin shock in the rat: role of the leukocyte,Circulatory Shock, 38:29-33 (1992).
Is there a therapeutic role for blood-brain barrier disruption?Annals of Internal Medicine, 93(1):137-139 (1980).
Abstract-XP002284974—Derwent Publications Ltd., (1996).
Browdy and Neimark PLLC
Marschel Ardin H.
Royds Leslie A.
LandOfFree
Method of treating or inhibiting the development of brain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating or inhibiting the development of brain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating or inhibiting the development of brain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3711575